Gedeon Richter PLC

Gedeon Richter PLC

RGEDF

$40.99

Updated: 23/09/2026, 13:44:30

Market Cap
$7.50B
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Country
HU
Stock valuation chart
One-year closing share-price history for RGEDF
Company Profile

Gedeon Richter PLC researches, develops, manufactures, markets, and sells pharmaceutical products. The company offers women's healthcare products for contraceptives, endometriosis, fertility, menopause, vaginal infections, and uterine fibroids, as well as Femtech, a digital therapeutic solution to enhance women's lives. It also provides central nervous system products, such as products for the treatment of chronic cerebral circulatory disorders and neuropathic pain; and anaesthetics, anti-anxiety medications, sleeping pills, and anti-epileptic medicines, as well as products for the prevention and treatment of various cardiovascular diseases. In addition, the company produces various over-the-counter products for various health problems comprising Panangin for heart support; Escapelle and Postinor, which are emergency contraceptive pills; Stopdiar and Nifuroxazide to treat diarrhea; RICHTER CycleBalance for infertility and PCOS; Curiosin for wound healing; Groprinosin for antiviral and immunostimulant; Folik, a pregnancy supplement; Moilec for back and joint pain; Fasconal, a pain relief tablet; Lordestin for allergies; Magnezin, a magnesium supplement; Aflamil, an anti-inflammatory and antirheumatic cream; and Oralsept, a sore throat and local anesthetic. Further, it engages in the provision of financial accounting, social and welfare, portfolio and management, catering, carriage transportation, engineering, quality control, asset management, and biotechnological manufacturing and research services; pharmaceutical retail; trading of biotech products; and sale of medical equipment. The company has strategic co-development and license agreement with Adalvo Ltd. for a proposed bioequivalent to Semaglutide injection, a GLP-1 receptor agonist indicated for chronic weight management. Additionally, it has a strategic research collaboration with FimmCyte AG for the development of first-in-class antibody, ‘FMC2', for the treatment of endometriosis. The company was founded in 1901 and is headquartered in Budapest, Hungary.

USD
OTC
CEO: Gabor Orban
Employees: 11,955
https://www.gedeonrichter.com
Asset Summaries
Latest generated summaries for RGEDF

No summaries found.

Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for RGEDF.
Share price
$40.99
Market cap
$7.50B
Exchange
OTC
Currency
USD
CEO
Gabor Orban
Employees
11,955
IPO date
17/10/2013
Beta
0.338
Last dividend
$0.00
Day range
$31.00 – $40.99
52-week range
$29.00 – $45.28
1-day performance
-0.08%
1-year performance
41.36%
Current drawdown (1Y)
-9.47%
CIK
N/A
CUSIP
N/A
ISIN
HU0000123096
Created
07/12/2025, 13:58:52
Last update
23/09/2026, 13:44:30

Track Gedeon Richter PLC with an AI analyst

See which prediction-market events move RGEDF, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to RGEDF from your Railway `news_articles` table.

No news found for this symbol.